APYX insider filings
Apyx Medical Corp — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-07-02. Screen APYX transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for APYX between 2026-07-10 and 2026-10-08. The table below lists the most recent filings on record.
Recent insider filings — Apyx Medical Corp
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-02 | 4 | Waldman Lawrence — Director | Option exercise (M): 12,000 @ $1.88 · Tax withholding (F): 5,024 @ $4.49 · Option exercise (M): 12,000 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Roman Shawn David — Chief Operating Officer | Option exercise (M): 15,000 @ $3.23 · Tax withholding (F): 10,533 @ $4.60 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Roman Shawn David — Chief Operating Officer | Grant/award (A): 88,044 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Levine Wendy Lauren — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Baylor-Henry Minnie — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Goodwin Charles D. II — Chief Executive Officer, Director | Grant/award (A): 213,948 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Vizirgianakis Stavros G. — Director | Grant/award (A): 450,000 @ $0 | EDGAR |
| 2026-06-15 | 4 | Waldman Lawrence — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | CITRONOWICZ MOSHE — Sr. V.P. of Operations | Grant/award (A): 63,392 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | HILL MATTHEW C — Chief Financial Officer | Grant/award (A): 132,066 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | CITRONOWICZ MOSHE — Senior Vice President | Option exercise (M): 37,000 @ $1.80 · Option exercise (M): 37,000 (derivative) @ $0 | EDGAR |
| 2026-01-29 | 4 | Roman Shawn David — Chief Operating Officer | Option exercise (M): 12,000 @ $1.80 · Option exercise (M): 12,000 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Levine Wendy Lauren — Director | Grant/award (A): 64,000 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Baylor-Henry Minnie — Director | Grant/award (A): 59,000 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Goodwin Charles D. II — Chief Executive Officer, Director | Grant/award (A): 193,000 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Vizirgianakis Stavros G. — Director | Grant/award (A): 128,000 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Waldman Lawrence — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | CITRONOWICZ MOSHE — Sr. V.P. of Operations | Grant/award (A): 36,000 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | HILL MATTHEW C — Chief Financial Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-03-03 | 4/A | HILL MATTHEW C — Chief Financial Officer | Purchase (P): 6,000 @ $1.13 | EDGAR |
| 2025-01-17 | 4 | Roman Shawn David — Chief Operating Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-01-17 | 4 | Levine Wendy Lauren — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-01-17 | 4 | Baylor-Henry Minnie — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-01-17 | 4 | Goodwin Charles D. II — Chief Executive Officer, Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-01-17 | 4 | Vizirgianakis Stavros G. — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-01-17 | 4 | Waldman Lawrence — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-01-17 | 4 | CITRONOWICZ MOSHE — Sr. V.P. of Operations | Grant/award (A): 36,000 (derivative) @ $0 | EDGAR |
| 2025-01-17 | 4 | HILL MATTHEW C — Chief Financial Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-08-13 | 4 | HILL MATTHEW C — Chief Financial Officer | Purchase (P): 5,336 @ $1.13 | EDGAR |
| 2024-08-12 | 4 | Levine Wendy Lauren — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2024-08-12 | 4 | Baylor-Henry Minnie — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2024-08-12 | 4 | Swandal Craig A. — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2024-08-12 | 4 | Andres John C. — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2024-08-12 | 4 | Vizirgianakis Stavros G. — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2024-08-12 | 4 | Waldman Lawrence — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2024-08-12 | 4 | Geraghty Michael — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2024-01-11 | 4 | Hornsby Todd — Executive Vice President | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-01-11 | 4 | Goodwin Charles D. II — Chief Executive Officer, Director | Grant/award (A): 243,000 (derivative) @ $0 | EDGAR |
| 2024-01-11 | 4 | CITRONOWICZ MOSHE — Sr. V.P. of Operations | Grant/award (A): 72,000 (derivative) @ $0 | EDGAR |
| 2024-01-11 | 4 | HILL MATTHEW C — Chief Financial Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2023-12-14 | 4 | HILL MATTHEW C — Chief Financial Officer | Purchase (P): 2,500 @ $2.19 | EDGAR |
| 2023-11-15 | 4 | Goodwin Charles D. II — Chief Executive Officer, Director | Purchase (P): 50,000 @ $1.57 | EDGAR |
| 2023-08-15 | 4 | Levine Wendy Lauren — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2023-08-15 | 4 | Baylor-Henry Minnie — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2023-08-15 | 4 | Swandal Craig A. — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2023-08-15 | 4 | Andres John C. — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2023-08-15 | 4 | Waldman Lawrence — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2023-08-15 | 4 | Geraghty Michael — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2023-08-15 | 4 | MAKRIDES ANDREW — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2023-07-19 | 4 | Waldman Lawrence — Director | Option exercise (M): 5,338 @ $2.97 · Option exercise (M): 12,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Apyx Medical Corp
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-29 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-07 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-24 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-21 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-11 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=APYX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →